HLTH:LSE:LSE-SPDR® MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 215.5

Change

-2.08 (-0.95)%

Market Cap

USD 0.18M

Volume

34.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-24 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R15:LSE SoftBank Group Corp.

N/A

USD 9,217.80B
0R1E:LSE Nintendo Co. Ltd.

N/A

USD 7,596.04B
0R1O:LSE Amazon.com Inc.

+4.00 (+2.20%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

+26.15 (+3.08%)

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.21 (+1.19%)

USD 617.54B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.09 (+0.61%)

USD 617.54B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
XDJP:LSE Xtrackers Nikkei 225 UCITS ETF..

+20.00 (+0.98%)

USD 348.03B
0QZK:LSE Coca-Cola Co.

-1.05 (-1.69%)

USD 266.08B
0QZO:LSE 0QZO

+1.70 (+1.53%)

USD 258.54B

ETFs Containing HLTH:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.13% 80% B- 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.13% 80% B- 73% C
Trailing 12 Months  
Capital Gain 6.62% 49% F 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.62% 47% F 55% F
Trailing 5 Years  
Capital Gain 62.46% 81% B- 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 62.46% 79% B- 80% B-
Average Annual (5 Year Horizon)  
Capital Gain 8.81% 68% D+ 70% C-
Dividend Return 8.81% 67% D+ 70% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.56% 73% C 85% B
Risk Adjusted Return 102.93% 98% N/A 99% N/A
Market Capitalization 0.18M 2% F 1% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.